Auris Medical is developing A&M-111 for the treatment of acute inner ear (sensorineural) hearing loss (ASNHL). AM-111 contains brimapitide, or D-JNKI-1 (D-stereoisomer of c-Jun N-Terminal Kinase Inhibitor 1), an inhibitor of the JNK stress kinase coupled to an intracellular transporter. AM-111 is formulated in a biocompatible and fully biodegradable gel and administered in a single dose intratympanic injection into the middle ear. From there the drug diffuses through the round window membrane into the cochlea.
A&M (Germany) 111 BTE Hearing Aid In Bangladesh